ROS1 and non-small cell lung carcinoma: Moreover, the absence of cfDNA mutations at TKIs failure was associated with better outcomes, suggesting the potential role of cfDNA testing as a surrogate biomarker for TKI treatment efficacy in ALK/ROS1 positive NSCLC patients [88].